The bling is back in gene technology. or is it?

Science & Technology Science & Nature
1

Contents WSJ B1. Paraphrased by our Microbiology Dept.

Most big pharmacy has waived the white flag on a specific gene tech while some small companies are plunging neck deep or more deeper.

2

Re: The bling is back in gene technology. or is it?

This technology attempts to "disable RNA molecules from translating genetic code into disease causing proteins." The Mercks and Pfizers gave up on this research since 2010. However Any lam Pharmaceuticals has two drugs that reduced disease producing proteins by 90 pct. Sanofi paid 21 pct premium to acquire 12 pct stake - 700M $ For those keeping score the mkt cap is 5 billion after adjusting for this premium.

3

Re: The bling is back in gene technology. or is it?

Celgene has offered to pay 2.57 bill US dollars (not the.worthless Canadian variety) for Nogra Pharma. Note that the RNA targeted drugs not even at late stage clinical trials.

Note that Alnylans market cap has doubled in last year. Is this hype or reality?

4

Re: The bling is back in gene technology. or is it?

Skeptics contend that most of the successes are in diseases based in "cells in the liver, which is more receptive to absorbing large molecule drugs such as those used to target RNA." Not much advance in diseases like cancer.

5

Re: The bling is back in gene technology. or is it?

It should be noted Merck in Jan sold Alnylans IP and other assets related to this area for 175 million $. A fraction of what Merck paid for the assets.

So what do our resident biologists microbiologist gene researchers and others pursuing related research think.

Long or short?

6

Re: The bling is back in gene technology. or is it?

Come on gang. I know there are some bio nerds geniuses in the US across the pond and most definitely on desiland. Kuch to bolo. I need one reply to get promoted - to a Turk.

7

Re: The bling is back in gene technology. or is it?

http://www.nature.com/nature/journal/v510/n7503/full/510035b.html

I like RNAi. My likes should be followed and funded.

8

Re: The bling is back in gene technology. or is it?

Thank you Mr. Ahmed for facilitating my promotion to Turk status. Funding will follow. Check is in the mail.

How is GILD working out for ya

9

Re: The bling is back in gene technology. or is it?

It was a simulator man. I only have sprint now in real. It's looking good if the merger happens. Still have made a decent return. Just forgetting about it.

Seriously though, it's pretty powerful research. I can't speak from the pharma (aka the dajjal) side but it will get funding from grants/educational side...

10

Re: The bling is back in gene technology. or is it?

Read the abstracts. Merck sells assets a tow price. Sanofi buys at high price. Big boys can afford to lose a dollar or two. Yes area looks promising. Not very knowledgeable about Dajjal research.

Didn't realize GILD was trial run. Good luck with Sprint.

11

Re: The bling is back in gene technology. or is it?

I was trying to highlight your good GILD pick. It more than doubled if I recall. I sold too early.

By the way Merck offered a 250 pct premium for a hepatitis drug company. Offered abt 3 billion. GILD went down a bit on the news.